Respective Roles of Thyroglobulin, Radioiodine Imaging, and Positron Emission Tomography in the Assessment of Thyroid Cancer

Seminars in Nuclear Medicine

Volumn 36, Issue 3, 2006, Pages 194-205

  Lind, Peter ^a   Kohlfürst, Susanne ^a  

^a GENERAL HOSPITAL KLAGENFURT   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IODINE 123; IODINE 124; IODINE 131; LEVOTHYROXINE; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; RADIOACTIVE IODINE; RADIOISOTOPE; RECOMBINANT THYROTROPIN; SOMATOSTATIN DERIVATIVE; TETROFOSMIN TC 99M; THYROGLOBULIN; THYROTROPIN;

ARTICLE; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER PATIENT; CERVICAL LYMPH NODE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DOSIMETRY; ECHOGRAPHY; FOLLOW UP; HIGH RISK PATIENT; HUMAN; LYMPH NODE METASTASIS; METABOLISM; METHODOLOGY; MORPHOLOGY; POSITRON EMISSION TOMOGRAPHY; RECURRENT DISEASE; RISK ASSESSMENT; THYROID CANCER; THYROIDECTOMY; WHOLE BODY SCANNER;

ADENOCARCINOMA, FOLLICULAR; BIOPSY, FINE-NEEDLE; CARCINOMA, PAPILLARY; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; IODINE RADIOISOTOPES; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; PREOPERATIVE CARE; RADIOMETRY; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; THYROGLOBULIN; THYROID NEOPLASMS; THYROID NODULE; THYROTROPIN; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED; TUMOR MARKERS, BIOLOGICAL;

EID: 33744535887     PISSN: 00012998     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.semnuclmed.2006.03.002     Document Type: Article

References (82)

1. Lind P., Kumnig G., Heinisch M., et al. Iodine supplementation in Austria. methods and results. Thyroid 12 (2002) 903-907
2. Rojewski M.T., and Gharib H. Nodular thyroid disease. Evaluation and management. N Engl J Med 313 (1985) 428-436
3. Watters D.A.K., Ahuya A.T., Evans R.M., et al. Role of ultrasound in the management of thyroid nodules. Am J Surg 164 (1992) 654-657
4. Gharib H., Goellner J.R., and Johnson D.A. Fine needle aspiration cytology of the thyroid. a 12 year experience with 11,000 biopsies. Clin Lab Med 13 (1993) 699-709
5. Carmeci C., Jeffrey R.B., McDougall I.R., et al. Ultrasound-guided fine-needle aspiration biopsy of thyroid masses. Thyroid 8 (1998) 283-289
6. Mikosch P., Gallowitsch H.J., Kresnik E., et al. Value of ultrasound-guided fine needle aspiration biopsy of thyroid nodules in an endemic goitre area. Eur J Nucl Med 27 (2002) 62-69
7. Lind P. Multi-tracer imaging of thyroid nodules. is there a role in the preoperative assessment of nodular goiter ?. (editorial). Eur J Nucl Med 26 (1999) 795-797
8. El-Desouki M. Tl 201 thyroid imaging in differentiating benign from malignant thyroid nodules. Clin Nucl Med 16 (1991) 225-230
9. Sundran F.X., and Mack P. Evaluation of thyroid nodules for malignancy using T-99m-sestamibi. Nucl Med Commun 16 (1995) 687-693
10. Mezosi E., Bajnok I., Gyory F., et al. The role of Tc-99m methoxy-isobutyl-isonitrile (MIBI) scintigraphy in the differential diagnosis of cold thyroid nodules. Eur J Nucl Med 26 (1999) 798-803
11. Kresnik E., Gallowitsch H.J., Mikosch P., et al. Tc-99m MIBI scintigraphy of thyroid nodules in an endemic goiter area. J Nucl Med 38 (1997) 62-65
12. Kresnik E., Gallowitsch H.J., Mikosch P., et al. Evaluation of thyroid nodules with Tc-99m tetrofosmin dual phase scintigraphy. Eur J Nucl Med 24 (1997) 716-721
13. Joensuu H., Ahonen A., and Klemi P.J. 18F-fluorodeoxyglucose imaging in the preoperative diagnosis of thyroid malignancy. Eur J Nucl Med 13 (1988) 502-506
14. Bloom A.D., Adler L.P., and Shuck J.M. Determination of malignancy of thyroid nodules with positron emission tomography. Surgery 114 (1993) 728-734
15. Uematsu H., Sadato N., Ohtsubo T., et al. Fluorine-18-fluorodeoxyglucose PET versus thallium-201 scintigraphy evaluation of thyroid tumors. J Nucl Med 39 (1998) 453-459
16. Mitchell J.C., Grant F., Evenson A.R., et al. Preoperative evaluation of thyroid nodules with (18)FDG-PET/CT. Surgery 138 (2005) 1166-1175
17. Sasaki M., Ichiya Y., Kuwabara Y., et al. An evaluation of FDG PET in the detection and differentiation of thyroid tumors. Nucl Med Commun 18 (1997) 957-963
18. Kresnik E., Gallowitsch H.J., Mikosch P., et al. Fluorine-18-fluorodeoxyglucose positron emission tomography in the preoperative assessment of thyroid nodules in an endemic goiter area. Surgery 133 (2003) 294-299
19. Van Herle A.J., and Uller R.P. Elevated thyroglobulin. a marker of metastases in differentiated thyroid carcinoma. J Clin Invest 56 (1975) 272-276
20. Pacini F., Lari R., Mazzeo S., et al. Diagnostic value of single serum thyroglobulin determination on and off thyroid supressive therapy in the follow-up of patients with differentiated thyroid cancer. Clin Endocrinol (Oxf) 23 (1985) 405-408
21. Ronga G., Fiorentino A., Paserio E., et al. Can iodine-131 whole body scan be replaced by thyroglobulin measurement in the postsurgical follow up of differentiated thyroid carcinoma?. J Nucl Med 31 (1990) 1766-1771
22. Ozata M., Suzuki S., Miyamoto T., et al. Serum thyroglobulin in the follow-up of patients with treated differentiated thyroid cancer. J Clin Endocrinol Metab 79 (1994) 98-105
23. Spencer C.A., Takeuchi M., Kazarosyan M., et al. Serum thyroglobulin autoantibodies. prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 83 (1998) 1121-1127
24. Pacini F. Follow up of differentiated thyroid cancer. Eur J Nucl Med suppl 2 (2002) S492-S496
25. Westbury C., Vini L., Fisher C., et al. Recurrent differentiated thyroid cancer without elevation of thyroglobulin. Thyroid 10 (2000) 171-176
26. Harder W., Lind P., Molnar M., et al. Thallium-201 uptake with negative I-131 scintigraphy and serum thyroglobulin in metastatic oxyphilic papillary thyroid carcinoma. J Nucl Med 39 (1997) 236-238
27. Cailaux A.F., Baudin E., Travagli J.P., et al. Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer?. J Clin Endocrinol Metab 85 (2000) 175-178
28. Pacini F., Cappezone M., Elisei R., et al. Diagnostic 131-iodine whole body scan may be avoided in thyroid cancer patients who have undetectable stimulated thyroglobulin levels after initial treatment. J Clin Endocrinol Metab 87 (2002) 1492-1495
29. Kohlfuerst S., Igerc I., and Lind P. Recombinant thyrotropin is helpful in the follow up and I-131 therapy of patients wirh thyroid cancer. a report of the results and benefits using recombinant human thyrotropin in clinical routine. Thyroid 15 (2005) 371-376
30. Pacini F., and Lippi F. Clinical experience with recombinant human thyroid-stimulating hormone (rhTSH). serum thyroglobulin measurement. J Endocrinol Invest 22 suppl (1999) 25-29
31. Robbins R.J., Chon J.T., Fleisher M., et al. Is the serum thyroglobulin response to recombinant human thyrotropin sufficient, by itsself, to monitor for residual thyroid carcinoma. J Clin Endocrinol Metab 87 (2002) 3242-3247
32. Wartofsky L. Management of low-risk well differentiated thyroid cancer based only on thyroglobulin measurement after recombinant human thyrotropin. Thyroid 12 (2002) 583-590
33. Menzel C., Zaplatnikov K., Diel M., et al. The influence of functional imaging in differentiated thyroid cancer. Nucl Med Commun 25 (2004) 239-243
34. Schlumberger M., Berg G., Cohen O., et al. Follow-up of low risk patients with differentiated thyroid carcinoma. a European perspective. Eur J Endocrinol 150 (2004) 105-112
35. Haber R.S. Role of ultrasonography in the diagnosis and management of thyroid cancer. Endocr Pract 6 (2000) 396-400
36. Mazzaferri E., Robbins R.J., Spencer C.A., et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 88 (2003) 1433-1441
37. Fatourechi V., and Hay I.D. Treating the patient with differentiated thyroid cancer with thyroglobulin-positive, iodine-131 diagnostic scan negative metastases. including comments on the role of serum thyroglobulin monitorinog in tumor surveillance. Semin Nucl Med 30 (2000) 107
38. Mazzaferri E., and Kloos R.T. Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation?. J Clin Endocrinol Metab 87 (2002) 1490-1498
39. Intenzo C.M., Jabbour S., Dam H.Q., et al. Changing concepts in the management of differentiated thyroid cancer. Semin Nucl Med 35 (2005) 257-265
40. Lind P., Igerc I., and Kohlfuerst S. Diagnosis, treatment and follow-up in case of differentiated thyroid cancer. Wien Med Wschr 19/20 (2005) 429-435
41. Waxman A., Ramanna L., Chapman N., et al. The significance of I-131 scan dose in patients with thyroid cancer: determination of ablation. Concise communication. J Nucl Med 22 (1981) 861-865
42. Lind P. I-131 whole body scintigraphy in thyroid cancer patients. Q J Nucl Med 43 (1999) 188-194
43. Dadparvar S., Krishna L., Slizofski W.J., et al. The role of Iodine-131 and Thallium-201 imaging and serum thyroglobulin in the management of differentiated thyroid carcinoma. Cancer 11 (1993) 3767-3773
44. Franceschi M., Kusic Z., Franceschi D., et al. Thyroglobulin determination, neck ultrasonography and iodine-131 whole-body scintigraphy in differentiated thyroid carcinoma. J Nucl Med 37 (1996) 446-451
45. Van-Sorge-Van Boxtel R.A.V., Van Eck-Smit B.L.F., and Goslings B.M. Comparison of serum thyroglobulin, I-131 and Tl-201 scintigraphy in the postoperative follow up differentiated thyroid cancer. Nuc Med Commun 14 (1992) 365-372
46. Filesi M., Signore A., Ventroni G., et al. Role of initial iodine-131 whole-body scan and serum thyroglobulin in differentiated thyroid carcinoma metastases. J Nucl Med 39 (1998) 1542-1546
47. Spies W.G., Wojtowicz C.H., Spies S.M., et al. Value of post-therapy whole-body 131-I imaging in the evaluation of patients with thyroid carcinoma having undergone high-dose 131-I therapy. Clin Nucl Med 14 (1989) 793-800
48. Sutter C.W., Masilungan B.G., and Stadalnic R.C. False positive results of 131-I whole-body scan in patients with thyroid cancer. Semin Nucl Med 25 (1995) 279-282
49. Lubin E., Mechlis-Frish S., Zatz S., et al. Serum thyroglobulin and iodine-131 whole-body scan in the diagnosis and assessment of treatment for metastatic differentiated thyroid carcinoma. J Nucl Med 35 (1994) 257-262
50. Simpson W.J., Panzarella T., Curruthers J.S., et al. Papillary and follicular thyroid cancer; impact of treatment in 1578 patients. Int J Rad Oncol Biol Phys 14 (1988) 1063-1075
51. Leger F.A., Izembart M., Dagousset F., et al. Decreased uptake of therapeutic doses of iodine-131 after 185 MBq iodine-131 diagnostic imaging for thyroid remnants in differentiated thyroid carcinoma. Eur J Nucl Med 25 (1998) 242-246
52. Coakly A.J. Thyroid stunning. Eur J Nucl Med 25 (1998) 203-204
53. Pineda J.D., Lee T., Ain K., et al. I-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. J Clin Endocrinol Metab 80 (1995) 1488-1492
54. Lind P. Should high hTg levels in the absence of iodine uptake be treated. Eur J Nucl Med 30 (2003) 157-160
55. Pace L., Klain M., Albanese C., et al. Short-term outcome of differentiated thyroid cancer patients receiving a second iodine-131 therapy on the basis of a detectable serum thyroglobulin level after initial treatment. Eur J Nucl Med Mol Imaging 33 (2006) 179-183
56. Ma C., Kuang A., Xie J., et al. Possible explanations for patients with discordant findings of serum thyroglobulin and 131I whole-body scanning. J Nucl Med 46 (2005) 1473-1480
57. Joensuu H., and Ahonen A. Imaging of metastases of thyroid carcinoma with fluorine-18-fluorodeoxyglucose. J Nucl Med 28 (1987) 910-914
58. Lind P., Gallowitsch H.J., Mikosch P., et al. Comparison of different tracers in the follow up of differentiated thyroid carcinoma. Act Med Austriaca 26 (1999) 115-118
59. Reske S.N., and Kotzerke J. FDG PET for clinical use. Results of the 3rd German Interdisciplinary Consensus Conference, "Onko PET III", 21. July and 19. September 2000. Eur J Nucl Med 28 (2001) 1707-1723
60. Feine U., Lizenmayer R., Hanke J.P., et al. Fluorine-18 FDG and iodine-131 uptake in thyroid cancer. J Nucl Med 37 (1996) 1468-1472
61. Grünwald F., Menzel C., Bender H., et al. Comparison of 18FDG-PET with 131-iodine and 99m Tc-sestamibi scintigraphy in differentiated thyroid cancer. Thyroid 7 (1997) 327-335
62. Lind P., Kresnik E., Kumnig G., et al. F-18-FDG PET in following up thyroid cancer. Acta Med Austriaca 30 (2003) 17-21
63. Conti P.S., Durski J.M., Bacqai F., et al. Imaging of locally recurrent and metastatic thyroid cancer with positron emission tomograpgy. Thyroid 9 (1999) 797-804
64. Altenvoerde G., Lerch H., Kuwert T., et al. Positron emission tomograpgy with F-18-deoxyglucose in patients with differentiated thyroid carcinoma, elevated thyroglobulin levels and negative iodine scans. Langenbecks Arch Surg 383 (1998) 160-163
65. Schluetter B., Bohuslavizki K.H., Beyer W., et al. Impact of FDG PET on patients with well differentiated thyroid cancer who present with elevated thyroglobulin and negative I-131 scan. J Nucl Med 42 (2001) 71-76
66. Moog F., Linke R., Manthey N., et al. Influence of thyroid-stimulating hormone levels on uptake of FDG in recurrent and metastatic differentiated thyroid carcinoma. J Nucl Med 41 (2000) 1989-1995
67. Petrich T., Börner A.R., and Weckesser E. Follow up of thyroid cancer patients using rhTSH-preliminary results. Nucl Med 40 (2001) 7-14
68. Ruf J., Lehmkuhl L., Bertram H., et al. Impact of SPECT and integrated low-dose CT after radioiodine therapy on the management of patients with thyroid carcinoma. Nucl Med Commun 25 (2004) 1177-1182
69. Lind P., and Igerc I. PET and PET/CT in the following up of thyroid cancer patients. In: Langsteger W., Sungler P., Lind P., et al. (Eds). Thyroid cancer four 2004 (2004), KOOP, Vienna (CD ROM)
70. Beyer T., Townsend D.W., Brun T., et al. A combination ofPET/CT scanner for clinical oncology. J Nucl Med 41 (2000) 1369-1379
71. Schöder H., Erdi Y.E., Larson S.M., et al. PET/CT. a new imaging technology in nuclear medicine. Eur J Nucl Med Mol Immaging 30 (2003) 1419-1437
72. Hausegger K., Reinprecht P., Kau T., et al. Clinical experience with a commercially available negative oral contrast medium in PET/CT. Fortschr Roentgenstr 177 (2005) 796-799
73. Lardinois D., Weder W., Hany T.F., et al. Staging of non-small-cell lung-cancer wirth integrated positron emissiontomography and computed tomography. N Engl J Med 348 (2003) 2500-2507
74. Burger I., Görres G., von Shulthess G., et al. PET/CT. diagnostic improvement in recurrent colorectal carcinoma compared to PET alone. Radiology 225 (2002) 424
75. Beyer T. Towards truly integrated hardware fusion with PET/CT. Nucl Med 44 suppl 1 (2005) S5-S12
76. Pietrzyk U. Does PET/CT render software registration obsolete?. Nucl Med 44 suppl 1 (2005) S13-S17
77. Czernin J., and Auerbach M.A. Clinical PET/CT imaging. Nucl Med 44 suppl 1 (2005) S18-S23
78. Ong S.C., Ng D.C., and Sundram F.X. Initial experience in use of fluorine-18-fluorodeoxyglucose positron emission tomographycomputed tomography in thyroid carcinoma patients with elevated thyroglobulin but negative iodine-131 whole body scans. Singapore Med 46 (2005) 297-301
79. Nahas Z., Goldenberg D., Fakhry C., et al. The role of positron emission tomographycomputed tomography in the management of recurrent papillary thyroid carcinoma. Laryngoscope 115 (2005) 237-243
80. Sgouros G., Kolbert K.S., Sheik A., et al. Patient- specific dosimetry for I-131 thyroid cancer therapy using I-124 PET and 3-dimensional-internal dosimetry (3D-ID) software. J Nucl Med 48 (2004) 1366-1372
81. Freudenberg L.S., Antoch G., Jentzen G., et al. Value of 124-I-PET/CT in staging of patients with differentiated thyroid cancer. Eur Radiol 14 (2004) 2092-2098
82. Lind P. Differentiated thyroid cancer. In: Ell P.J., and Gambhir S.S. (Eds). Nuclear Medicine in Clinical Diagnosis and Treatment (2004), Churchill Livingstone, Edinburgh 145-164